Navigation Links
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Date:4/28/2009

    FDA confirms durable pain palliation as an acceptable primary endpoint
    for a regulatory submission in support of market approval

BOTHELL, WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a second Phase 3 registration trial of OGX-011, its lead product candidate targeting castrate resistant prostate cancer (CRPC), via the Special Protocol Assessment (SPA) process. The FDA has agreed that the design and planned analysis of our Phase 3 trial featuring durable pain palliation as the primary endpoint adequately addresses the objectives necessary to support a regulatory submission.

"We have now received confirmations on two separate Phase 3 trial designs from the FDA via the SPA process, each in second-line treatment of advanced prostate cancer," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "One trial design evaluates overall survival benefit while the second trial design evaluates reduction in pain as the primary endpoint. Having evaluated both of these endpoints in our Phase 2 trials, we are well positioned to re-evaluate each of these endpoints in larger Phase 3 registration trials."

"The FDA's acknowledgement of pain in addition to survival as key endpoints for market approval supports the basis of our OGX-011 development program for advanced prostate cancer," added Cormack. "Although we observed a positive effect on PSA in our Phase 2 trials of OGX-011, we recognize that PSA response has not been shown to correlate to a clinical benefit and therefore is not an acceptable endpoint for FDA approval. Our focus remains on survival and pain palliation, both endpoints that FDA has confirmed are appropriate for marketing approval, and both endp
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  The In Silico ... that will be featured at the conference, which takes ... on December 3 and 4, 2014. Researchers, students, drug ... to hear the following: KEYNOTE SPEAKERS ... Diego Skaggs School of Pharmacy Drug ...
(Date:9/17/2014)... San Jose, California (PRWEB) September 17, 2014 ... disintegrated by naturally occurring microorganisms such as bacteria, ... subsequently transformed into water, methane, biomass, inorganic compounds, ... With enhanced processability, expanding customer base and improved ... environmentally beneficial and economically viable alternative to conventional ...
(Date:9/17/2014)... 2014 Terracon Corporation has announced the ... tank . This addition to the company’s industry-leading ... linear polyethylene and available in 125 or 250 gallon ... in two weeks or less. , The new pre-engineered ... in Terracon’s existing TerraPure tank line – plus quick ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3
... , Strategic Examination and Consolidation of Services Recommended ... 27 Little uniformity exists in the structure or functions of ... to Clinical Trials Offices: What,s New in Research Administration?, ... (AAHC). Emerging centralized clinical trial offices (CTOs) are among the ...
... , , ATLANTA, Aug. 27 ... million extension of its Series C financing which was originally completed in ... $5 million in Series C preferred stock received warrants for an additional ... have up to 30 days from the delivery of Phase III top-line ...
... , , , ... ATLANTA, Aug. 27 Airo, recognized maker of the ... Safe handset is available for delivery Q4 of 2009. Airo ... in potentially explosive environments like Petroleum, Chemicals, Fertilizer, Coal, Propane, ...
Cached Biology Technology:Clinical Trials Offices Changing Academic Health Center Research Infrastructure 2Alimera Sciences Closes $5 Million in Extended Series C Financing 2Airo Wireless Announces the Release of the Intrinsically Safe A25is Cell Phone/PDA 2
(Date:9/17/2014)... significantly faster since the 1960s. The typical development phases ... have accelerated -- by as much as 70 percent. ... by scientists from Technische Universitt Mnchen based on long-term ... observed since 1870. Their findings were published recently in ... dieback" was a hot topic, with the very survival ...
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... North American Menopause Society (NAMS) has published its ... midlife womenon everything from hot flashes to heart ... Society Recommendations for Clinical Care of Midlife Women," ... Menopause . This is the first, comprehensive ... midlife women freely available to all clinicians who ...
Breaking Biology News(10 mins):Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3Sharks' skin has teeth in the fight against hospital superbugs 2
... July 20, 2011Researchers at the U.S. Department of Energy,s ... Center have found a potential key for unlocking the ... leaves and stalks, or switch grass. In a ... Chemical Society , Los Alamos researchers S. Gnanakaran, Giovanni ...
... sleuthing the 2010 Deepwater Horizon oil spill, a research team ... chemicals were contained in a deep, hydrocarbon-containing plume. The ... mapped and sampled it last summer in the Gulf of ... spill. The researchers took a major step in explaining ...
... Bureau of Reclamation and Fluid Imaging Technologies Inc. have ... the capacity and speed of Fluid Imaging Technologies, FlowCAM ... larvae in water samples. The spread of mussels ... impair or interrupt water delivery and hydropower generation functions ...
Cached Biology News:Researchers find potential key for unlocking biomass energy 2Chemical make-up of Gulf of Mexico plume determined 2Chemical make-up of Gulf of Mexico plume determined 3Chemical make-up of Gulf of Mexico plume determined 4Reclamation signs research agreement to improve quagga and zebra mussel larvae detection 2
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... working in a regulated environment, Pipette ... calibration software that automates gravimetric pipette ... framework that meets todays regulatory compliance ... secure solution that includes a full ...
... of the yolk protein Vtg in plasma from ... sensitive biomarker for endocrine disrupting chemicals (EDCs) with ... become an accepted screening test for the estrogenic ... trout) EIA kit is a double-antibody immunometric (sandwich) ...
... (RTL) can provide you with the ... method development and validation ,Performance of ... of your GMP manufacturing environment ,Assurance ... a full spectrum of microbiological services ...
Biology Products: